Beyondspring INC 8-K filings

BeyondSpring announced its second-quarter 2026 financial results, highlighting positive clinical data for Plinabulin and a strategic leadership transition to advance its lead DUBLIN-4 program.

BeyondSpring Inc. announces leadership changes effective July 1, 2026, with Min Qiu appointed CEO and Na Li as CFO, to focus on the DUBLIN-4 Phase 3 program.

BeyondSpring Inc. announced its first-quarter 2026 financial results, highlighting advancements in its Plinabulin and SEED Therapeutics programs, with a focus on enhancing cancer therapies.

BeyondSpring Inc. announced its full-year 2025 financial results, highlighting significant clinical progress for Plinabulin and strategic advancements for SEED Therapeutics.

BeyondSpring Inc. announced a delay in the second closings of its previously disclosed sale of Series A-1 Preferred Shares of SEED Therapeutics Inc. until the first half of 2026.

BeyondSpring Inc. announced the closing of a private placement, raising $2.0 million through the sale of 800,000 ordinary shares to Ray Beauty Group Limited.

BeyondSpring Inc. announced its third-quarter 2025 financial results, highlighting positive clinical data for Plinabulin and significant milestones for its co-founded entity, SEED Therapeutics.

SEED Therapeutics, a clinical-stage biotechnology company, announced the completion of its $30 million Series A-3 financing and FDA clearance for its lead program, ST-01156, targeting RBM39.

BeyondSpring Inc. shareholders ratified the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, at the annual meeting held on September 15, 2025.

BeyondSpring Inc. reported Q2 2025 financial results, highlighting promising clinical advances for Plinabulin and FDA clearance for SEED Therapeutics' ST-01156, alongside a strengthened cash position.

BeyondSpring Inc. has announced its 2025 annual meeting of shareholders for September 15, 2025, establishing a record date of July 25, 2025, and a shareholder proposal deadline of July 14, 2025.

BeyondSpring announced its Q1 2025 financial results, highlighting promising clinical data for Plinabulin in combination therapies for NSCLC and Hodgkin lymphoma patients who have failed PD-1/L1 inhibitors, and progress in its SEED Therapeutics program.

BeyondSpring Inc. announces the resignation of Marcum LLP as its independent registered public accounting firm and the engagement of CBIZ CPAs P.C. effective April 9, 2025.

BeyondSpring Inc. announced its 2024 year-end financial results, highlighting clinical progress for Plinabulin and strategic advancements for SEED Therapeutics.

BeyondSpring Inc. completed the initial closing of its asset sale, transferring shares of SEED Therapeutics Inc. to multiple buyers for $7.35 million in cash proceeds.

BeyondSpring Inc. has entered into agreements to sell a portion of its equity in SEED Therapeutics for $35.4 million, which will be used to advance clinical trials for its lead asset, Plinabulin.

BeyondSpring Inc. will now file as a U.S. domestic issuer, requiring more detailed and prompt reporting to the SEC, effective January 1, 2025.